PDCD1 and Miyoshi myopathy: Tim‐3‐GAL9 axis provides inhibitory immune signals to activated T cells,51 and immunotherapy targeting Tim‐3 and PD‐1 pathways enables the reversion of T‐cell exhaustion and restoration of antitumor immunity,52 thus suggesting a possible use of this strategy to reconstruct anti‐MM immunity.